ReviewBMJ (Clinical research ed.)2004
Taking account of future technology in cost effectiveness analysis.
Review in BMJ (Clinical research ed.), 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Pramipexole and levodopa in early Parkinson's disease: dynamic changes in cost effectiveness.PharmacoEconomics · 2005Trial
- The long-term effects of domestic and international tuberculosis service improvements on tuberculosis trends within the USA: a mathematical modelling study.The Lancet. Public health · 2024Article
- Optimizing patient treatment decisions in an era of rapid technological advances: the case of hepatitis C treatment.Health care management science · 2017Article
- Comment on: "Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy".PharmacoEconomics · 2015Article
- Population- versus cohort-based modelling approaches.PharmacoEconomics · 2012Article
- Accounting for the drug life cycle and future drug prices in cost-effectiveness analysis.PharmacoEconomics · 2011Article
- Comparing the cost effectiveness of risperidone and olanzapine in the treatment of schizophrenia using the net-benefit regression approach.PharmacoEconomics · 2009Article
- Modelling downstream effects in the presence of technological change.PharmacoEconomics · 2008Article
- Modeling the impact of genetic screening technologies on healthcare: theoretical model for asthma in children.Molecular diagnosis & therapy · 2007Article
- Optimal assignment of treatments to health states using a Markov decision model: an introduction to basic concepts.PharmacoEconomics · 2006Article
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.